Orchestra Therapeutics (fka OCHTQ)

[Renee]

OCHTQ revoked:

http://www.sec.gov/litigation/admin/2012/34-67288.pdf

[Renee]

OCHTQ SEC Suspension:

http://www.sec.gov/litigation/suspensions/2012/34-66939.pdf

http://www.sec.gov/litigation/suspensions/2012/34-66939-o.pdf

ADMIN Proceeding:

http://www.sec.gov/litigation/admin/2012/34-66938.pdf

[hoerud]

New ticker: ochtq

[surf1944]

Says it all in the IHUB:

The stock symbol has gone from IMNR to IMRP to now OCHT(stay away from this company for now)

Orchestra Therapeutics Discontinues Its HIV Vaccine Development Program
Tuesday July 17, 8:22 pm ET

CARLSBAD, Calif., July 17 /PRNewswire-FirstCall/ -- Orchestra Therapeutics, Inc. (OTC Bulletin Board: OCHT - News) announced today the discontinuation of its HIV Vaccine Development Program. Analysis of data from 70 patients who completed a 52 weeks clinical trial in Europe and Canada did not show a clear advantage of Orchestra Therapeutics' second generation HIV vaccine, IR103, over its original whole-killed HIV vaccine, REMUNE®. Furthermore, although interim analysis of patients in this trial at 36 weeks suggested a trend toward stabilization of CD4+ counts in HAART naive patients vaccinated with REMUNE® or IR103, this trend was not observed at week 52.

"While recognizing that the sample size is too small to achieve statistical significance, these results are, nonetheless, less than we had expected," said Joseph F. O'Neill, MD MPH President and CEO of Orchestra Therapeutics. "We are deeply appreciative of the support that our investors, clinical researchers, and patients have given to development of this approach to an HIV vaccine and know that knowledge gained through our efforts will contribute to the eventual discovery of an immune therapy for HIV/AIDS. Our company, however, does not have the resources to move this program forward at this time."

Dr. O'Neill also announced that Orchestra has contracted with PharmaBioSource Realty, LLC to act as a broker to sell its HIV vaccine production facility located in King of Prussia, Pennsylvania. "Selling the assets of this facility will bring new capital into the company, help us to further reduce our burn rate, and thereby strengthen Orchestra's potential to emerge as the world's leading autoimmune immunotherapy company in the months and years ahead."

Orchestra Therapeutics is exploring a number of strategic options for disposition of its other HIV assets. These include sale or donation of its HIV related intellectual property to an entity interested in pursuit of whole killed HIV vaccine technology. Dr. Peter Salk, a member of Orchestra's HIV Scientific Advisory Committee, commented that "The rationale for investigation of a whole killed virus approach to an HIV/AIDS vaccine remains strong. I trust that the effort that Orchestra Therapeutics has made will stimulate other researchers' interest and effort in this field. The HIV/AIDS epidemic is far too devastating to leave any stone unturned in the quest for an effective vaccine."

About Orchestra Therapeutics

Orchestra Therapeutics, Inc., formerly The Immune Response Corporation (OTC Bulletin Board: OCHT, formerly IMRP), is an immuno-pharmaceutical company focused on the discovery and development of novel treatments for autoimmune diseases. The Company's lead immune-based therapeutic product candidate is NeuroVax(TM) for the treatment of MS. In addition to MS, the Company has proprietary technology and prior clinical experience for evaluation of TCR peptide-based immune therapies for RA and psoriasis.

The targeted strategy behind the Company's immune-based therapies is reflected in the name Orchestra. Rather than disrupting the function of the entire immune system, these therapeutic vaccines are designed to elicit a very specific response -- akin to correcting one instrument in an orchestra that is out of tune -- to help control disease.

This news release contains forward-looking statements. Forward-looking statements are often signaled by forms of words such as should, could, will, might, plan, projection, forecast, expect, guidance, potential and developing. Actual results could vary materially from those expected due to a variety of risk factors, including whether the Company will continue as a going concern and successfully raise proceeds from financing activities sufficient to fund operations and clinical trials of NeuroVax(TM), the uncertainty of successful completion of any such clinical trials, the fact that the Company has not succeeded in commercializing any drug, the risk that NeuroVax(TM) might not prove to be effective as a therapeutic vaccine, whether future trials will be conducted and whether the results of such trials will coincide with the results of NeuroVax(TM) in preclinical trials and/or earlier clinical trials. A more extensive set of risks is set forth in Orchestra Therapeutics' SEC filings including, but not limited to, its Annual Report on Form 10-K for the year ended December 31, 2006, and its subsequent Quarterly Report filed on Form 10-Q. The Company undertakes no obligation to update the results of these forward-looking statements to reflect events or circumstances after today or to reflect the occurrence of unanticipated events.

NeuroVax(TM) is a trademark of Orchestra Therapeutics, Inc. REMUNE® is a registered trademark of Orchestra Therapeutics, Inc.

MEDIA CONTACT: INVESTOR CONTACT:
Rachel Kessler Robert Giordano
Chamberlain Communications Group ROI Associates
[phone] [phone]
[e-mail] [e-mail]

COMPANY CONTACT:
Michael K. Green, COO
Orchestra Therapeutics, Inc.
[phone]
[e-mail]


Source: Orchestra Therapeutics, Inc.

[choctaw]

NEWS.....disaster!!!

[jculp]

Anyone know why the recent slide upwards is happening?

[surf1944]

IMRP is now OCHT, trying to hide under a new symbol & name:

Orchestra Therapeutics Announces New Trading Symbol
Monday April 16, 4:00 am ET

CARLSBAD, Calif., April 16 /PRNewswire-FirstCall/ -- Orchestra Therapeutics, Inc. (OTC Bulletin Board: OCHT, formerly IMRP), an immuno- pharmaceutical company focused on the discovery and development of novel treatments for autoimmune diseases, announced today that effective April 16 the Company's new trading symbol will be OCHT. Also effective on April 16, 2007, the Company's publicly traded "Class B" warrants will trade under the symbol OCHTZ.

"This marks an exciting moment in the Company's history as Orchestra Therapeutics transforms itself into an innovative and dynamic company grounded in the autoimmune platform," said Dr. Joseph O'Neill, President and CEO of Orchestra Therapeutics, Inc.

About Orchestra Therapeutics

Orchestra Therapeutics, Inc., formerly The Immune Response Corporation (OTC Bulletin Board: OCHT, formerly IMRP), is an immuno-pharmaceutical company focused on the discovery and development of novel treatments for autoimmune diseases. The Company's lead immune-based therapeutic product candidate is NeuroVax(TM) for the treatment of multiple sclerosis (MS). In addition to MS, the Company has proprietary technology and prior clinical experience for clinical evaluation of TCR peptide-based immune-based therapies for rheumatoid arthritis (RA) and psoriasis. The targeted strategy behind the Company's autoimmune therapies is reflected in the name Orchestra. Rather than disrupting the function of the entire immune system, these therapeutic vaccines are designed to elicit a very specific response -- akin to correcting one instrument in an orchestra that is out of tune -- to help control disease.

Autoimmune processes are implicated in more than 60 conditions, including MS, RA, Crohn's disease, psoriasis, lupus and type-1 diabetes. Orchestra Therapeutics' unique approach to controlling autoimmune diseases uses small peptide vaccines that appear to stimulate FOXP3+ Regulatory T-cells; a component of the immune system that is now recognized as being key in autoimmune pathogenesis.

In MS, for example, a specific subset of a patient's own white blood cells, pathogenic T-cells, attack myelin, a fatty tissue in the central nervous system, which surrounds and protects nerve fibers. This pathologic process creates multiple areas of inflammation that ultimately lead to scarring (sclerosis) and that interfere with normal transmission of nerve impulses. This nerve damage, in turn, leads to a variety of chronic and often debilitating neurological symptoms, ranging from serious movement and balance problems to vision impairment.

NeuroVax(TM), an investigational T-Cell Receptor peptide vaccine for the treatment of relapsing-remitting forms of MS, appears to work by enhancing levels of FOXP3+ Regulatory T-cells within the immune system, which may help control levels of pathogenic T-cells in MS patients. Data from the Company's most recent Phase II clinical trial in MS showed that reduced levels of FOXP3 can be restored to normal levels after repeated vaccinations with NeuroVax(TM). The Company recently announced the injection of the first patient in a large multi-center Phase II study to assess the safety and efficacy of NeuroVax(TM).

Recognizing that a growing base of scientific research has demonstrated the potential significance of the role of FOXP3+ Regulatory T-cells in the prevention and treatment of a variety of autoimmune diseases, the Company has made the strategic decision to emphasize this program and redirected its resources toward the execution and expansion of product development in this area.

The Company is in discussions with several academic institutions to conduct pre-clinical work on therapeutic vaccines to treat psoriasis and RA. Based on findings to be derived from these product development programs, the Company plans to initiate Phase I trials in one of these new autoimmune areas in 2008. The Company also has two HIV product candidates, Remune® and IR103. The 52-week data from the first large cohort of HIV clinical trial participants from a now-terminated Phase II clinical trial have already been gathered, and analysis of the data will be completed and disclosed in the second quarter of 2007. Based on this data, the Company will consider strategic alternatives for the HIV program.

This news release contains forward-looking statements. Forward-looking statements are often signaled by forms of words such as should, could, will, might, plan, projection, forecast, expect, guidance, potential and developing. Actual results could vary materially from those expected due to a variety of risk factors, including whether the Company will continue as a going concern and successfully raise proceeds from financing activities sufficient to fund operations and clinical trials of NeuroVax(TM), Remune® or IR103, the uncertainty of successful completion of any such clinical trials, the fact that the Company has not succeeded in commercializing any drug, the risk that NeuroVax(TM), Remune® or IR103 might not prove to be effective as either a therapeutic vaccine, whether future trials will be conducted and whether the results of such trials will coincide with the results of NeuroVax(TM), Remune® or IR103 in preclinical trials and/or earlier clinical trials and the unresolved status of the Company's HIV program. A more extensive set of risks is set forth in Orchestra Therapeutic's SEC filings including, but not limited to, its Annual Report on Form 10-K for the year ended December 31, 2006, and its subsequent Quarterly Reports to be filed on Form 10-Q. The Company undertakes no obligation to update the results of these forward- looking statements to reflect events or circumstances after today or to reflect the occurrence of unanticipated events.

NeuroVax(TM) is a trademark of Orchestra Therapeutics, Inc. Remune® is a registered trademark of Orchestra Therapeutics, Inc.

MEDIA CONTACT: INVESTOR CONTACTS:
Rachel Kessler Robert Giordano
Chamberlain Communications Group Inc. ROI Associates
[phone] [phone]
[e-mail] [e-mail]

Gene Marbach
COMPANY CONTACT: Makovsky & Company
Michael K. Green, COO [phone]
Orchestra Therapeutics, Inc. [e-mail]
[phone]

[surf1944]

IMRP selling more stock(stay away):

Form 8-K for IMMUNE RESPONSE CORP

12-Apr-2007

Unregistered Sale of Equity Securities


Item 3.02 Unregistered Sales of Equity Securities.

As previously reported, in March 2006 we closed a private placement of secured convertible notes and warrants to accredited investors. The notes had an aggregate original principal amount of $8,000,000. The conversion price of the notes is (giving effect to our December 2006 1-for-100 reverse stock split) $2.00 per share. The noteholders also received warrants entitling them to (giving effect to our December 2006 1-for-100 reverse stock split) purchase 12,000,000 shares of our common stock at $2.00 per share. The warrants were divided into two tranches, each consisting of warrants to (giving effect to our December 2006 1-for-100 reverse stock split) purchase 6,000,000 shares. The unexercised warrants from the first tranche expired on August 7, 2006.

In March 2007, we entered into a Warrant Exercise and Price Protection arrangement with certain warrant holders of the 2006 Private Placement. This arrangement included a special warrant exercise inducement whereby (i) the warrant holder would receive 2.5 shares of our common stock for each $2.00 of second tranche warrant exercise price paid to us (this equates to an effective price of $0.80 per share) and (ii) the warrant holder would receive short-term ratchet-style price protection (through September 30, 2007) on March 2007 warrant exercises.

In addition to all previously reported exercises of second tranche warrants under this Warrant Exercise and Price Protection arrangement, we issued 206,250 shares of our common stock to exercising warrantholders paying an aggregate exercise price of $165,000.

All unexercised investor warrants from the 2006 private placement have now expired.

The 206,250 warrant exercise shares were issued to the two accredited investor warrantholders pursuant to the Securities Act Section 4(2) registration exemption.

As previously reported, our placement agent in the 2006 Private Placement, Spencer Trask Ventures, Inc. ("STVI") is entitled to receive $1.00 (giving effect to our December 2006 1-for-100 reverse stock split) and an additional seven-year placement agent warrant for each five noteholder warrants which are exercised. As a result of the exercise of 82,500 noteholder warrants as described above, STVI became entitled to $16,500 in cash and 16,500 additional placement agent warrants. The exercise price per share of the 16,500 additional placement agent warrants arising from the above noteholder warrant exercises will be $0.80 instead of $2.00, as a result of an amendment related to the Warrant Exercise and Price Protection arrangement. STVI, which is an affiliate of Kevin Kimberlin, who is a director and major stockholder of us, has allocated a portion of the additional placement agent warrants to various brokers and employees and its parent company. These additional placement agent warrants will be issued to STVI and its assignees pursuant to the Securities Act Section 4(2) registration exemption.

Top of the Form

[surf1944]

IMRP may have a trading bottom here, but I would sell the bounce that it has & enter at even lower prices.

[surf1944]

I would just stay away from this one for now. You'll need increased volume going into IMRP before you want to enter it(my guest is the PPS action will be on the downside first)

[Fedex11 ©]

apparently we saw the bottom lol NOW i need to see the top so i can make some money off of this thing this was my first stock ever bought in a couple years ago


FEDEX11

[americano]

Am watching for a bottom and a possible quick trade next year, I normally hold but this one will give a couple good trades if I can guess near bottom I figure, like before an upgrade on a trial

[surf1944]

I would agree on that, I'm also just watching this one and it could very well test a new low before heading back up.

surf

[americano]

I think they have a ways to come down but at some point this one may be worht a small gamble again, have it on watch, and I think it will come down a bunch more, if I guy can find the bottom of it , I be you could do good but its been pretty bleak to say the least with the fall in this stock.

I did make good money in the hey day though, don't know if I will buy back in at any poin but watching it anyway.

[jabberstox]

I can attest to that....my x use to work for them....bad mgmt doesnt even cover it!!!!

[Hawaii-x]

I really, really, dislike this company. Remember when it was $13-15 back in 2000. POOR Management.

[americano]

I will check back in too it. I almost started aboard before

[americano]

I use to trade this stock years ago and make money but I bought some early this year and sold at a loss, because I was conserned they wouldn't make it, maybe good I may wastch what develops for fun and who knows , over all I made money in the hey days

[surf1944]

Just did a 100 for 1 Reverse Split....On the watch list.

surf